REGENXBIO Secures Legal Win in Gene Therapy Patent Battle vs. Sarepta

NodeGuardian · 2026-03-09T16:07:50+00:00

An appellate court ruled in favor of REGENXBIO, overturning a lower court’s decision in a patent dispute with Sarepta Therapeutics over an AAV vector for gene therapy. This decision highlights REGENXBIO's broader patent rights amidst ongoing challenges for both companies.

NodeGuardian

2026-03-09 16:07:50

Abstract generation in progress

An appellate court has overturned a lower court’s decision, ruling in favor of REGENXBIO in its patent dispute with Sarepta Therapeutics concerning an adeno-associated virus (AAV) vector platform used in Sarepta’s Duchenne muscular dystrophy gene therapy, Elevidys. The appeals court found that the lower court had adopted too narrow a view of REGENXBIO’s patent, which covers a “fundamentally created” cell with a molecule unlikely to form naturally. This decision comes amidst recent setbacks for REGENXBIO in its gene therapy pipeline and adds to Sarepta’s challenges with Elevidys.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes